Skip to content
Pharma Observatory a Scientist.com platform

Clinical trial

An Exploratory, Placebo-controlled, Double-blind, Phase II Study of the Efficacy and Safety for Rituximab (Genetical Recombination) in Myalgia Encephalomyelitis/Chronic Fatigue Syndrome (ME/CFS)

NCT06952413 is registered in ClinicalTrials.gov with National Center of Neurology and Psychiatry, Japan as lead sponsor.

NCT NCT06952413
Email me this page as a PDF

Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.

Get the NCT06952413 report as a PDF

The PDF carries up to 50 rows of each section, where the page shows the first few, with the sources listed. Enter a work email and confirm it from the message we send, and the report follows by email.

Registry record

As filed in ClinicalTrials.gov.

Title
An Exploratory, Placebo-controlled, Double-blind, Phase II Study of the Efficacy and Safety for Rituximab (Genetical Recombination) in Myalgia Encephalomyelitis/Chronic Fatigue Syndrome (ME/CFS)
Lead sponsor
National Center of Neurology and Psychiatry, Japan
Phase
Phase 2
Overall status
Recruiting
Start date
April 9, 2025
Completion date
October 31, 2027
Enrollment
30 (estimated)
Sites
1

Conditions

As the registry lists them; a condition with its own page is linked.

myalgia encephalomyelitis/chronic fatigue syndrome (me/cfs)